What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pain
- Main trialPhase 1
- “The purpose of this study will be to characterize the pharmacokinetic (PK) profile of the Fixed-Dose Combination (FDC) IBU 62.5 milligram (mg)/APAP 125 mg per 5 milliliter (mL) suspension in children 6 to 11 years of age, inclusive, to satisfy Pediatric Research Equity Act (PREA) requirements.”In the company’s words, NCT07632274 on ClinicalTrials.gov
Other drugs for Pain
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- DLBS1442Dexa Medica Group · Phase 2/3
- CebranopadolAdneuris Therapeutics, Inc. · Tris Pharma, Inc. · Phase 3
- CombogesicAFT Pharmaceuticals, Ltd. · Phase 3
- Product DNN.63.18.040Ache Laboratorios Farmaceuticos S.A. · Phase 3
- Urcosimod ophthalmicOkyo Pharma Ltd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Sep 2026 | A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026